Mumbai

The B.V. BIO-CORP manufactures products by its different segments like Biotech and Hitech (Trace minerals and complete range of Biosecurity product) using state-of-art technology combined with the research and innovative spirit of its qualified professionals. The division having years of experience of handling vitamins and its premixes through its highly accredited manufacturing plant (ISO 9001:2008, ISO 22000:2005, HACCP, GMP and FAMIQS). Along the vitamin premixes also have a range of proven probiotics, immunomodulators & other yeast based roducts. Disinfectant division established decades ago to give complete of biosecurity solutions. Complete disinfectant range of products to serve the poultry industry. Newly launched Aqua segment geared up to serve the aqua industry thorough its Health product, Vitamin premixes and Biosecurity solutions.

CPhI’s 7th Annual Pharma IPR Conference happening on 7-9 March 2018, Mumbai is a leading platform for Indian pharmaceutical companies to interact with the IP Attorneys and Counsels from across the globe and discuss the recent trends and best practices in the pharma IPR space. Since 2012, Pharma IPR Conference has focused on importance of Intellectual Property in Pharma syncing it with business objectives of Indian Pharma companies.  This three-day conference will provide ample opportunities for business networking with visionary entrepreneurs and industry experts around the world.

Data Integrity (DI) has become a focal point of FDA inspections, as is evidenced by the number of warning letters citing data integrity and the resulting number of import alerts. Company Quality Management Systems are being scrutinized as to how the integrity of raw data (both electronic and manual) generated in the Quality Control Laboratory and in Operations (Manufacturing and Engineering) can be assured. The FDA is now including recommendations for recipients to obtain 3rd party assistance when addressing DI issues.  Indicators of potential Data Integrity issues are an unreasonably low number of deviations, OOS incidents and EM excursions.  Regulatory non-compliance is always a serious area of concern for the Indian pharmaceutical sector. With 13 warning letters being issued in FY 2015 and 9 warning letters in FY 2016, Data Integrity still continues to be a severe problem to be tackled.

This is a question we’ve asked ourselves over and over. It’s how we at Medtronic have made hearts beat stronger and longer. It’s how we’ve pushed the limits of what technology can do in and for the body. It’s how we will continue to alleviate pain, restore health and extend life. Rising costs, an aging population, and the burden of chronic disease impact us all. And no single entity in the healthcare system can solve these challenges alone. That’s why we’re stepping forward. That’s why we’re prepared to put the full power of our technologies, services, resources — and our people — to work with new partners, in new ways, to usher in a new era in healthcare.

Post : Sales Representative II

Medpace’s dedicated teams serve as an extension of your team – we engage quickly and provide strategic thinking – ensuring quicker start-up times, superior quality, and the most efficient delivery of every phase of your clinical trial. Our therapeutic and regulatory experts are committed to streamlining your path to approval so every partnership is designed to create research solutions focused on your critical needs.

Post : Project Coordinator

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post : Sr. Executive PAC

Merck Limited (formerly E. Merck Limited) was set up in India as the first Merck subsidiary in Asia in 1967.  The Company operates both its Pharmaceuticals and Chemicals businesses in the country. Merck was also the first Merck Group Company to go public in the year 1981.  The Merck Group now holds 51% of the share capital in Merck Limited, while the remaining 49% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.  Merck Specialities Pvt. Ltd., the wholly owned Indian subsidiary of Merck KGaA, was incorporated in 2005.

Post : Allergy Science Associate

One of the most notable developments in the S&T sector in the XI Plan has been the setting up of the Science and Engineering Research Board (SERB) through an Act of Parliament, viz. the Science and Engineering Research Board Act, 2008. Promoting basic research in Science and Engineering and to provide financial assistance to persons engaged in such research, academic institutions, research and development laboratories, industrial concerns and other agencies for such research and for matters connected therewith or incidental thereto are the primary and distinctive mandate of the Board.  SERB aims to build up best management systems which would match the best global practices in the area of promotion and funding of basic research.